Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Development of mullerian inhibiting substance as an anti-cancer drug.

Cate RL, Ninfa EG, Pratt DJ, MacLaughlin DT, Donahoe PK. Development of mullerian inhibiting substance as an anti-cancer drug. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 1:641-7.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.